Antitrust enforcement against Big Tech generates a lot of noise — lawsuit filings, dramatic testimony, verdict headlines — but very little of that noise is the actual economic event. The event is the remedy: the specific, court-ordered or negotiated change to how a company is allowed to operate or what it's allowed to own. A remedy is a policy lever with a direct line to corporate cash flow, because it either forces a dominant company to share a chokepoint it used to control alone, or it forces that company to give up a piece of itself outright.\n\nThis matters for investors because remedies create clean, nameable winners in a way that abstract "regulatory risk" doesn't. When a court orders a platform to open its app store to alternative payment processors, that's not vague pressure — it's a specific set of companies (payment processors, app developers, alternative marketplaces) gaining a specific new right. When a settlement requires divesting a business line, that's not vague pressure either — it's a spinoff with its own ticker, or a named acquirer with a new asset. The mechanism is traceable, which means it's trackable.\n\nThe goal of this guide is to give you the durable framework for reading antitrust remedies the way a policy-to-profit investor should: what kind of remedy you're looking at, who structurally benefits from that kind of remedy regardless of which company is involved, and where to find the primary documents that tell you the real timeline — because the stock move usually happens well before the mainstream coverage catches up to the fine print.